➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
Medtronic
Moodys
McKinsey

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR KEYTRUDA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for KEYTRUDA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01953692 A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) Recruiting Merck Sharp & Dohme Corp. Phase 1 2013-11-01 The purpose of this trial is to evaluate the safety, tolerability, and efficacy of pembrolizumab (MK-3475, KEYTRUDA®) in hematologic malignancies. The primary study hypotheses are that treatment with pembrolizumab will result in a clinically meaningful improvement in Objective Response Rate (ORR) or Complete Remission Rate (CRR).
NCT02009449 A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Recruiting ARMO BioSciences Phase 1 2013-11-01 This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of AM0010 in patients with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.
NCT02036502 A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) Recruiting Merck Sharp & Dohme Corp. Phase 1 2014-02-01 This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory Multiple Myeloma (rrMM), and in combination with carfilzomib and low-dose dexamethasone in participants with relapsed or refractory Multiple Myeloma (rMM). This study is being done to find the maximum tolerated dose (MTD)/maximum administered dose (MAD) and recommended Phase 2 dose (RP2D), and to evaluate the safety and tolerability of pembrolizumab (MK-3475) when given in combination with standard of care (SOC) treatments in participants with rrMM or rMM. Preliminary efficacy data will also be assessed. The primary study hypothesis is that these combinations are sufficiently well tolerated to permit further clinical investigation.
NCT02054520 Immunotherapy Study for Patients With Stage IV Melanoma Recruiting NewLink Genetics Corporation Phase 2 2014-06-01 The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with the experimental immunotherapy drug, dorgenmeltucel-L, for melanoma. We hypothesize that this form of combinatorial immunotherapy will result in tumor stabilization or shrinkage, significant prolongation of progression-free, disease-free or overall survival compared to the use of immune checkpoint inhibitors alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for KEYTRUDA

Condition Name

Condition Name for KEYTRUDA
Intervention Trials
Melanoma 25
Breast Cancer 18
Non-Small Cell Lung Cancer 17
Head and Neck Cancer 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for KEYTRUDA
Intervention Trials
Carcinoma 104
Breast Neoplasms 58
Lung Neoplasms 57
Carcinoma, Non-Small-Cell Lung 57
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for KEYTRUDA

Trials by Country

Trials by Country for KEYTRUDA
Location Trials
United States 575
Spain 24
Australia 19
Japan 19
United Kingdom 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for KEYTRUDA
Location Trials
California 67
Texas 66
Massachusetts 50
New York 32
Illinois 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for KEYTRUDA

Clinical Trial Phase

Clinical Trial Phase for KEYTRUDA
Clinical Trial Phase Trials
Phase 4 1
Phase 3 16
Phase 2/Phase 3 2
[disabled in preview] 261
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for KEYTRUDA
Clinical Trial Phase Trials
Not yet recruiting 291
Recruiting 164
Active, not recruiting 10
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for KEYTRUDA

Sponsor Name

Sponsor Name for KEYTRUDA
Sponsor Trials
Merck Sharp & Dohme Corp. 228
National Cancer Institute (NCI) 92
M.D. Anderson Cancer Center 38
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for KEYTRUDA
Sponsor Trials
Other 467
Industry 383
NIH 93
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Moodys
AstraZeneca
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.